PSYENCE BIOMEDICAL LTD. (PBM)

Company

PSYENCE BIOMEDICAL LTD. (PBM)

SPAC: Newcourt Acquisition Corp (NCAC)

StatusJan 26, 2024
BiotechnologyBiotechnology
Merger / DESPACMerger / DESPAC
  1. 0%SPAC/IPOIPOOct 2021
    0%SPAC/IPOIPOOct 2021
  2. 25%LOILOI
    25%LOILOI
  3. 50%AgreementDealJan 2023
    50%AgreementDealJan 2023
  4. 75%Merger voteVoteNov 2023
    75%Merger voteVoteNov 2023
  5. 100%MergerMergerJan 2024
    100%MergerMergerJan 2024
1Y 2M10M1M

Merger · Jan 2024

SPAC/IPO details
1 unit consists of 1 share + 1/2 Warrant
Prospectus volume (424B4)220 m USD22,000,000 Units · 10 USD/Unit
IPO closed (8-K)250 m USD25,000,000 Units · 10 USD/Unit

Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

Learn more at www.psyencebiomed.com and on LinkedIn.

Chart/Sentiment

Financials

Scroll to Top